Covid: Pfizer and BioNTech promise new vaccine in 100 days

Posted on Nov 26, 2021 4:47 PMUpdated Nov 26, 2021, 4:49 PM

After the worry, the reaction. While a new variant of the coronavirus, detected in South Africa and potentially more contagious than the previous ones, raises since Friday unheard of fears since the advent of Delta, BioNTech said it immediately launched investigations to determine whether a new vaccine should to be developed or not.

“We understand the concern of the experts and immediately launched investigations into the B.1.1.529 variant,” said the company that developed with Pfizer the most widely used COVID-19 vaccine in the Western world. BioNTech is still awaiting additional data from the laboratories, which should be sent to it within the next two weeks and will determine whether the Pfizer BioNTech vaccine needs to be reworked.

A proven process

In this scenario, both partners would be able to redesign their product within six weeks and ship the first batches within 100 days, BioNTech announced. “We have a proven process whereby a new vaccine is available within 100 days if it is really needed. However, before a new vaccine against a new variant is widely available, it must be approved. It is not our decision. The decision must be taken by the regulatory authorities and the government institutions concerned, ”Uğur Şahin, who founded BioNTech with his wife Özlem Türeci, explained to“ Echoes ”in July.

Global authorities reacted alarmingly to the new variant on Friday, with the European Union and Britain notably stepping up border controls while scientists sought to find out whether the mutation was resistant to vaccines. It is for the moment “premature” to envisage an adaptation of the vaccines to the new variant, estimated for its part the European Medicines Agency.

With Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *